A brand new trial is underway to trial a drug which may combat dyskinesia in people with Parkinson’s.
The phase 2 study is being funded by a partnership across Parkinson’s UK and the Michael J Fox Foundation in the USA to test a new drug, NLX-112, in people with Parkinson’s.
NLX-112 works by targeting serotonin producing brain cells which are believed to contribute to the development of dyskinesia, a commonly experienced side effect in those with Parkinson’s who have been taking levodopa-based medication for several years.
The biopharma company Neurolixis will lead the study and will assess safety and tolerance of NLX-112 as well as its impact on reducing dyskinesia and some non-motor symptoms including mood and sleep problems.
Posted in: Parkinson's News